← Back
Data updated: Mar 10, 2026
SHANGHAI HENLIUS BIOTECH
OncologyImmunologyOphthalmology
SHANGHAI HENLIUS BIOTECH is a biotechnology company focused on Oncology, Immunology, Ophthalmology.
2025
Since
3
Drugs
-
Trials
3
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 82%
2 drugs Phase 3: 15 Phase 2: 20 Phase 1: 16
Immunology 7%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Ophthalmology 6%
0 drugs Phase 3: 2 Phase 1: 1
Gastroenterology 5%
0 drugs Phase 3: 1 Phase 2: 2
Pipeline Strength Pro
Loading...